Pfizer announced that the FDA has approved Abrysvo, the company’s bivalent RSV prefusion F, or RSVpreF, vaccine, for the prevention of LRTD and severe LRTD caused by RSV in infants from birth up to six months of age by active immunization of pregnant individuals at 32 through 36 weeks gestational age. Abrysvo is unadjuvanted and composed of two preF proteins selected to optimize protection against RSV A and B strains.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on PFE:
- Novavax (NASDAQ:NVAX) Surges Following Success Against COVID-19 Variants
- CureVac price target lowered to $8 from $10 at BofA
- Moderna’s (NASDAQ:MRNA) Updated COVID Vaccine Effective Against Eris Variant
- Will BioNTech’s (NASDAQ:BNTX) COVID-19 Vaccine Sales Reaccelerate?
- Cantor biotech/biopharma analysts to hold analyst/industry conference call